drugset
drugset / Trial / NCT00319228

Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate

NCT00319228 ↗

Phase 2/3 Active not recruiting 30 enrolled Grifols Biologicals, LLC
NaSingle-groupOpen-labelPrevention

Summary

To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.

Timeline

Start
2006-01
Primary completion
2028-12
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ATIII-DAF/DI Protein / enzyme biologic 50 iu/kg Intravenous

Indications

hereditary antithrombin deficiency